The Food and Drug Administration on Monday approved a shot to protect infants and vulnerable toddlers against respiratory syncytial virus, or R.S.V., offering one of the first protections for an illness that fills children’s hospitals year after year. The monoclonal antibody shot is expected to be available at the start of the fall R.S.V. vaccine by Pfizer for pregnant women that is meant to protect infants from the virus. can cause serious disease in infants and some children and results in a large number of emergency department and physician office visits each year,” Dr. John Farley, an official in the F.D.A. “Today’s approval addresses the great need for products to help reduce the impact of R.S.V.

---

Persons: ” Dr, John Farley, “ Organizations: Drug Administration, Pfizer, Sanofi, AstraZeneca, Centers for Disease Control, Center, Drug, Research